Baseline Week 12 % change p value
All treated patients (n = 70)          
Total cholesterol (mg/dL) 228.8 ± 29.0 198.0 ± 26.1 -13.0 ± 10.1 <0.001
Triglycerides (mg/dL) 136.4 ± 110.3 119.1 ± 89.4 -5.0 ± 46.2 N.S.
TG ³ 150 mg/dL (n = 20) (mg/dL) 249.7 ± 145.1 182.2 ± 100.6 -23.1 ± 28.9 0.005
HDL cholesterol (mg/dL) 54.1 ± 12.3 56.9 ± 12.6 5.9 ± 11.0 <0.001
HDL cholesterol <40 mg/dL (n = 5) (mg/dL) 32.8 ± 5.9 36.0 ± 6.0 10.5 ± 11.5 N.S.
LDL cholesterol (mg/dL) 145.2 ± 21.3 115.6 ± 23.1 -19.7 ± 16.2 <0.001
RLP cholesterol (mg/dL) 5.8 ± 5.4 4.4 ± 2.8 -13.4 ± 29.9 <0.001
RLP cholesterol ³5.2 (n = 23) (mg/dL) 10.1 ± 7.7 6.1 ± 4.1 -34.4 ± 25.7 <0.001
Cholesterol absorption marker/total cholesterol (mg/mg*103) 7.1 ± 3.7 5.8 ± 2.1 -11.9 ± 26.4 <0.001
Cholesterol synthesis marker/total cholesterol (mg/mg*103) 1.8 ± 1.2 3.1 ± 1.7 90.8 ± 59.4 <0.001
Fasting blood glucose (mg/dL) 146.8 ± 49.2 147.6 ± 37.9 8.2 ± 39.0 N.S.
A1C (%) 7.4 ± 0.8 7.5 ± 0.9 1.8 ± 6.2 N.S.
CPR (ng/mL) 1.7 ± 1.1 1.7 ± 1.1 29.2 ± 106.6 N.S.
hs-CRP (ng/mL) 1183.2 ± 1542.6 792.9 ± 866.6 -5.8 ± 57.0 0.003
Monotherapy (n=57)          
Total cholesterol (mg/dL) 228.9 ±28.4 199.4 ± 25.3 -12.5 ± 9.5 <0.001
Triglycerides (mg/dL) 135.4 ± 110.5 117.0 ± 94.0 -7.5 ± 47.8 N.S.
TG ³ 150 mg/dL (n = 17) (mg/dL) 241.9 ± 150.4 180.9 ± 107.3 -21.2 ± 30.8 0.02
HDL cholesterol (mg/dL) 54.2 ± 12.6 57.6 ± 13.2 6.8 ± 10.4 <0.001
HDL cholesterol <40 mg/dL (n = 4) (mg/dL) 32.8 ± 5.9 36.0 ± 6.0 10.5 ± 11.5 N.S.
LDL cholesterol (mg/dL) 146.7 ± 21.2 115.5 ± 21.0 -20.7 ± 13.7 <0.001
RLP cholesterol (mg/dL) 5.8 ± 5.4 4.3 ± 3.0 -16.0 ± 30.0 0.001
RLP cholesterol ³5.2 (n = 20) (mg/dL) 9.7 ± 7.7 6.0 ± 4.4 -34.5 ± 26.1 0.002
Cholesterol absorption marker/total cholesterol (mg/mg*103) 6.7 ± 2.7 5.7 ± 1.8 -10.7 ± 25.1 <0.001
Cholesterol synthesis marker/total cholesterol (mg/mg*103) 1.9 ± 1.2 3.3 ± 1.6 93.6 ± 61.7 <0.001
Fasting blood glucose (mg/dL) 145.5 ± 47.0 149.3 ± 38.3 9.4 ± 38.8 N.S.
A1C (%) 7.3 ± 0.8 7.4± 0.9 1.6 ± 8.6 N.S.
CPR (ng/mL) 1.6 ± 1.1 1.7 ± 1.1 34.1 ± 110.7 N.S.
hs-CRP (ng/mL) 1089.7 ± 1346.2 717.7 ± 705.0 -5.3 ± 56.9 0.011
Combination (Ezetimibe + Statins) therapy (n=13)          
Total cholesterol (mg/dL) 222.0 ± 33.7 194.9 ± 29.6 -11.0 ± 16.5 0.029
Triglycerides (mg/dL) 137.5 ± 105.6 127.8 ± 58.3 6.7 ± 33.2 N.S.
TG³150 mg/dL (n=3) (mg/dL) 293.7 ± 125.0 189.3 ± 62.7 -33.8 ± 12.3 N.S.
HDL cholesterol (mg/dL) 53.7 ± 11.8 53.9 ± 9.4 2.0 ± 12.7 N.S.
HDL cholesterol <40 mg/dL (n=1) (mg/dL) 32.8 ± 5.9 36.0 ± 6.0 10.5 ± 11.5 N.S.
LDL cholesterol (mg/dL) 141.0 ± 20.2 114.2 ± 32.3 -15.5 ± 24.5 0.009
RLP cholesterol (mg/dL) 5.6 ± 5.3 4.5 ± 2.0 -2.5 ± 28.1 N.S.
RLP cholesterol ³5.2 (n=3) (mg/dL) 12.5 ± 8.6 6.9 ± 2.1 -33.6 ± 27.4 N.S.
Cholesterol absorption marker/total cholesterol (mg/mg*103) 9.1 ± 6.6 6.5 ± 3.0 -17.4 ± 32.4 <0.05
Cholesterol synthesis marker/total cholesterol (mg/mg*103) 1.3 ± 1.0 2.2 ± 1.8 78.8 ± 48.4 <0.05
Fasting blood glucose (mg/dL) 152.1 ± 60.0 140.3 ± 36.6 2.6 ± 40.9 N.S.
A1C (%) 7.5 ± 0.8 7.6 ± 0.7 2.6 ± 5.4 N.S.
CPR (ng/mL) 2.0 ± 1.3 1.7 ± 1.1 7.9 ± 87.1 N.S.
hs-CRP (ng/mL) 1009.1 ± 1037.1 775.0 ± 692.8 -5.2 ± 62.1 N.S.
A1C, hemoglobin A1C; CPR: C-peptide reactivity, hs-CRP: high-sensitivity C-reactive protein, HDL: high density lipoprotein, LDL: low density lipoprotein, RLP: remnant-like lipoprotein. CPR (reference value): 1.2 to 2.0 ng/mL.
Table 3: Effect of ezetimibe in 70 patients with hyper-LDL-cholesterolemia